TrialPLoS pathogens2022

SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.

Dina Khateeb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.